IDRx, Inc.
Clinical trials sponsored by IDRx, Inc., explained in plain language.
Now part of
GSK plc
GSK
NYSE
Biotech developing targeted cancer therapies, owned by GSK.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New pill shows promise for tough stomach cancer in early trial Results expected Mar 2027 (estimated)